Source comparison
Route-Specific Dosing: Subcutaneous vs Intravenous Protocols
Subcutaneous administration is the standard route for reproductive endocrine research. It mimics the pulsatile endogenous kisspeptin release from ARC neurons while maintaining stable plasma levels for 60–90 minutes post-injection. A 2024 trial in Human Reprodu
This comparison does not assign a generated winner or score.
- Subcutaneous administration is the standard route for reproductive endocrine research. It mimics the pulsatile endogenous kisspeptin release from ARC neurons while maintaining stable plasma levels for 60–90 minutes post-injection. A 2024 trial in Human Reproduction administered 0.24, 1.0, and 3.2 nmol/kg kisspeptin-10 subcutaneously to women with hypothalamic amenorrhea and tracked LH pulsatility via blood sampling every 10 minutes for six hours. The 1.0 nmol/kg dose restored LH pulse frequency to 1 pulse per 90 minutes (matching healthy controls), while 0.24 nmol/kg produced subthreshold receptor activation and 3.2 nmol/kg caused receptor desensitisation evidenced by blunted response to subsequent doses.
- Intravenous infusion is reserved for metabolic signalling studies where researchers need to maintain supraphysiological kisspeptin concentrations across extended observation windows. The plasma half-life of kisspeptin-10 in humans is 28 minutes following IV bolus. Meaning single-dose effects dissipate within 120 minutes as peptide clearance outpaces receptor recycling. Continuous IV infusion at 4.0 nmol/kg over 75 minutes maintains plasma kisspeptin above the GPR54 activation threshold (estimated 15–20 nM based on in vitro data) throughout the observation period. Studies investigating kisspeptin's effects on insulin sensitivity, glucose disposal, and thermogenesis consistently use this infusion protocol because subcutaneous bolus dosing produces variable plasma peaks that confound metabolic endpoint measurement.
- Absorption kinetics differ substantially between routes. Subcutaneous injection achieves peak plasma concentration (Tmax) at 22–35 minutes with bioavailability approximating 65–70% compared to IV. This delayed absorption smooths the receptor activation curve. GnRH neurons experience gradual kisspeptin elevation rather than the acute spike produced by IV bolus, which better replicates endogenous kisspeptin neuron firing patterns. For protocols aiming to restore physiological GnRH pulsatility (ovulation induction trials, hypogonadotropic hypogonadism studies), subcutaneous dosing at 1.0 nmol/kg every 90 minutes produces LH pulse patterns indistinguishable from healthy controls.